Left Ventricular Assist Device Ups QoL in Ambulatory Heart Failure

Share this content:
Left Ventricular Assist Device Ups QoL in Ambulatory Heart Failure
Left Ventricular Assist Device Ups QoL in Ambulatory Heart Failure

FRIDAY, Jan. 13, 2017 (HealthDay News) -- Left ventricular assist devices (LVADs) improve quality of life in ambulatory patients with advanced heart failure, but increase lifetime costs, according to a study published online Jan. 11 in JACC: Heart Failure.

Jacqueline Baras Shreibati, M.D., from the Stanford University School of Medicine in California, and colleagues examined the cost-effectiveness of LVADs in ambulatory patients with advanced heart failure. The costs of care were determined among Medicare beneficiaries before and after LVAD implant in 2009 to 2010. These costs and efficacy data from the literature were used in a Markov model to project the incremental cost-effectiveness ratio (ICER) of destination LVAD therapy versus medical management.

The researchers found that LVAD implant had a mean cost of $175,420. The mean cost of readmission was significantly lower before versus after LVAD ($12,377 versus $19,465; P < 0.001), while similar monthly outpatient costs were seen ($3,364 versus $2,974; P = 0.54). Compared with medical management, LVAD increased quality-adjusted life-years (4.41 versus 2.67), readmissions (13.03 versus 6.35), and costs ($726,200 versus $361,800) in the lifetime simulation model, yielding an ICER of $209,400 per quality-adjusted life-year gained and $507,400 per life-year gained. These results were sensitive to LVAD readmission rates and costs of outpatient care; if these parameters were 50 percent lower the ICER would be $86,900.

"LVADs may provide good value if outpatient costs and adverse events can be reduced," the authors write.

Several authors disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »